Drug Profile
BMS 986360
Alternative Names: BMS-986360; CC 90001; CC-539Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Developer Bristol-Myers Squibb; Celgene Corporation
- Class Amides; Anti-inflammatories; Antifibrotics; Butylamines; Cyclohexanols; Hepatoprotectants; Pyrimidines; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Phase I Solid tumours
- Discontinued Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jun 2023 Celgene terminates a phase II trial in Idiopathic pulmonary fibrosis in the US, the UK, Australia, Colombia, Canada, Brazil, Greece, Germany, Romania, Taiwan, Turkey, Russia, Ukraine (PO) due to changes in business objective (EudraCT2016-003473-17) (NCT03142191)
- 09 Dec 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Canada, Australia, USA (unspecified route) (NCT05625412; 700358917)
- 09 Dec 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Canada, Australia, USA (unspecified route) (NCT05625412; 700358917)